Accueil   Diary - News   All news THERANEXUS ANNOUNCES ISSUANCE OF CHINESE PATENT COVERING ITS DRUG CANDIDATE THN102

THERANEXUS ANNOUNCES ISSUANCE OF CHINESE PATENT COVERING ITS DRUG CANDIDATE THN102

 

 

 

Lyon, 24 April 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces the issuance of a Chinese patent for its drug candidate THN102. This patent was granted to the French Alternative Energies and Atomic Energy Commission (CEA) by the Chinese State Intellectual Property Office (SIPO). The patent issuance fee was paid on 27 March 2019. Theranexus holds exclusive rights to the patent.

 


This CN 105579041 B patent, whose inventors are listed as Franck Mouthon (CEO) and Mathieu Charvériat (CSO), is entitled "Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug". It protects the drug candidate THN102, which combines flecainide as an anti-connexin agent and modafinil as a psychotropic drug, until 2034. This patent covers a therapeutic composition containing flecainide and modafinil, to treat, for example, excessive daytime sleepiness in patients suffering from Parkinson's disease or narcolepsy, to boost memory in healthy patients, or to keep them awake during long periods of time. The two active ingredients can be administered simultaneously or staggered over time. Flecainide is used to potentiate the effect of modafinil.

 

 

Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree